Verteporfin Photodynamic Therapy Cohort Study: Report 2: Clinical Measures of Vision and Health-Related Quality of Life

@article{Reeves2009VerteporfinPT,
  title={Verteporfin Photodynamic Therapy Cohort Study: Report 2: Clinical Measures of Vision and Health-Related Quality of Life},
  author={Barnaby C Reeves and Julia Langham and Jemma L. Walker and Richard Grieve and Usha Chakravarthy and Keith F Tomlin and James Carpenter and Carla Guerriero and Simon Peter Harding},
  journal={Ophthalmology},
  year={2009},
  volume={116 12},
  pages={2463-70}
}
PURPOSE To quantify decreases in health-related quality of life (HRQoL) for given deterioration in clinical measures of vision; to describe the shape of these relationships; and to test whether the gradients of these relationships change with duration of visual loss. DESIGN A prospective, longitudinal study of patients treated with verteporfin photodynamic therapy in the United Kingdom National Health Service. PARTICIPANTS Patients with neovascular age-related macular degeneration (AMD… CONTINUE READING